iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat sight threatening ocular allergies and various systemic disease indications; and Oral AmpB Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections. The company was founded in 2005 and is headquartered in Vancouver, Canada.
Why Firing Your Internet Provider Could Save You $19,494 (Ad)
A brand-new technology - code named "Halo-Fi" - could kill off your overpriced cable company for good... beaming lightning-fast internet to your home for an estimated $7 a month.
This is undoubtedly the beginning of the end for "Big 3" internet providers.
Forward-thinking investors in Halo-Fi are lining up to get rich before January 30th.
